The file's text, extracted by GovTribe without its formatting.
Notice of Intent The Naval Medical Logistics Command (NMLC) intends to award a sole source contract under the authority of FAR 13.106-1(b)(1) to Life Technologies Corporation of 5781 Van Allen WAY Carlsbad, California 92008-7321 for the delivery of the described requirement in support of the Naval Medical Research Unit No. 6 (NAMRU-6), Lima-Peru. The requirement is for reagents and consumables in support of NAMRU-6.
PERFORMANCE WORK STATEMENT
The Virology & Emerging Infections Department of the U.S. Naval Medical and Research Unit No. 6 (NAMRU-6) is seeking to purchase laboratory reagents and equipment to be used for molecular diagnosis of influenza virus, adenovirus, Metapneumovirus, Enterovirus, Rhinovirus, Respiratory Syncytial Virus, Mayaro, dengue, Chikungunya, Zika, and SARS-CoV-2 virus. Specifically, requirement involves PCR enzymes for reverse transcription, real-time platforms, and Illumina that are used for detection of human influenza viruses (Influenza A-matrix gene and B) and its subtypes (H3, H1pdm/SwH1N1, H1 seasonal and H5) (SOP N6-VIR-MB RV 014); sequencing full genome of influenza A using random amplification and pathogen discovery protocols in Illumina platform; detecting genetic material of Adenovirus in nasal and pharyngeal swab specimens (SOP N6-VIR-MB RV 007); detecting the genetic material of Metapneumovirus (MPV), Enterovirus, Rhinovirus and Respiratory Syncytial Virus in nasal and pharyngeal swabs specimens using a reverse transcription (N6-VIR-MB RV 006); and, amplification of the whole genome of the influenza A virus based on the amplification of full-length gene segments for SNP genotyping, gene expression analysis and genotype (N6-VIR-MB RV 001) and pathogen discovery in respiratory and serum samples collected in our surveillance protocols.
All these NAMRU-6 assays have been validated using the TaqMan 7500/7500 Fast Real time PCR system and MiSeq and MiniSeq Illumina platform and therefore, compatibility of the consumables is a requirement. The RT-PCR assays have been developed independently for each SOP and involve much time and effort by laboratory technicians, and supervisors for final approval. Reagents used must remain the same as the ones indicated in the SOPs, otherwise the design and validation of these processes would have to start from scratch, which would delay all processing and the timely diagnosis of public health relevant pathogens.
NAMRU-6 will require items purchased to be shipped following the reagent specific cold-chain requirements (dry ice, refrigeration or room temperature) in two installments. First shipment should be sent as soon as award is signed, and second shipment should be sent four months afterwards.
Materials should be shipped according to the following schedule:
| Item # |
| Cat # |
| Item |
| Qty. |
| Shipment # 1 |
| Shipment # 2 |
| 1 |
| 7002 |
| RNase AWAY™ Surface Decontaminant (Spray Bottle) |
| 11 |
| 9 |
| 2 |
| 2 |
| 4306311 |
| MicroAmp™ Clear Adhesive Film |
| 8 |
| 4 |
| 4 |
| 3 |
| 4316813 |
| MicroAmp™ Optical 96-Well Reaction Plate |
| 3 |
| 2 |
| 2 |
| 4 |
| 4323032 |
| MicroAmp™ Optical 8-Cap Strips |
| 43 |
| 30 |
| 13 |
| 5 |
| 4346907 |
| MicroAmp™ Fast Optical 96-Well Reaction Plate, 0.1 mL |
| 56 |
| 32 |
| 24 |
| 6 |
| 4351979 |
| TaqMan RNase P Instrument Verification Plate, Fast 96-well (for 0.1 mL block) |
| 3 |
| 3 |
| 0 |
| 7 |
| 4432250 |
| Array Card Calibration Install Kit (QS7) |
| 1 |
| 1 |
| 0 |
| 8 |
| 4432364 |
| Region of Interest (ROI) and Background Plates, 96-well (QS5) |
| 1 |
| 1 |
| 0 |
| 9 |
| 4432382 |
| 96-Well 0.2-mL TaqMan™ RNase P Instrument Verification Plate (QS5) |
| 1 |
| 1 |
| 0 |
| 10 |
| 4432557 |
| Calibration Install Kit, Fast 96-well (QS7) |
| 1 |
| 1 |
| 0 |
| 11 |
| 4444436 |
| TaqMan Fast Virus 1-Step master mix |
| 25 |
| 14 |
| 11 |
| 12 |
| 12351050 |
| Platinum™ SuperFi™ DNA Polymerase (2U/ul) |
| 4 |
| 4 |
| 0 |
| 13 |
| 16500500 |
| UltraPure™ Agarose |
| 2 |
| 2 |
| 0 |
| 14 |
| 18090050 |
| SuperScript™ IV Reverse Transcriptase (200U/ul) |
| 2 |
| 2 |
| 0 |
| 15 |
| 18090200 |
| SuperScript™ IV Reverse Transcriptase (200U/ul) |
| 2 |
| 2 |
| 0 |
| 16 |
| 18091200 |
| SuperScript™ IV First-Strand Synthesis System |
| 5 |
| 5 |
| 0 |
| 17 |
| 10297-018 |
| dNTP Set (100 mM) |
| 7 |
| 7 |
| 0 |
| 18 |
| 10787-018 |
| 1 Kb Plus DNA Ladder |
| 8 |
| 4 |
| 4 |
| 19 |
| 10977-015 |
| UltraPure™ DNase/RNase-Free Distilled Water |
| 50 |
| 25 |
| 25 |
| 20 |
| 11732-088 |
| SuperScript III Platinum One-Step qRT-PCR Kit |
| 19 |
| 10 |
| 9 |
| 21 |
| 11736-051 |
| SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit |
| 4 |
| 2 |
| 2 |
| 22 |
| 12594100 |
| SuperScript™ IV One-Step RT-PCR System |
| 10 |
| 5 |
| 5 |
| 23 |
| 75001.1.ML |
| ExoSAP-IT™ Express PCR Product Cleanup |
| 5 |
| 5 |
| 0 |
| 24 |
| A26343 |
| QuantStudio™ 3/5 10-Dye Spectral Calibration Kit, 96-well, 0.2 mL (QS5) |
| 1 |
| 1 |
| 0 |
| 25 |
| A28522 |
| TaqPath™ 1-Step Multiplex Master Mix (No ROX) |
| 5 |
| 3 |
| 2 |
| 26 |
| AM2238 |
| TURBO™ DNase (2 U/µL) |
| 2 |
| 2 |
| 0 |
| 28 |
| AM9935 |
| RT-PCR Grade Water |
| 40 |
| 26 |
| 14 |
| 29 |
| N8010560 |
| MicroAmp™ Optical 96-Well Reaction Plate, 0,2 mL |
| 27 |
| 21 |
| 6 |
| 30 |
| Q32854 |
| Qubit® dsDNA HS Assay Kit |
| 5 |
| 3 |
| 2 |
| 31 |
| Q32855 |
| Qubit RNA HS Assay Kits |
| 5 |
| 3 |
| 2 |
| 32 |
| Q32856 |
| Qubit assays tubes |
| 5 |
| 3 |
| 2 |
| 33 |
| S33102 |
| Syber Safe DNA gel Stain |
| 5 |
| 3 |
| 2 |
| 34 |
| A28568 |
| QuantStudio™ 5 Real-Time PCR System, 96-well, 0.1 mL, Laptop computer |
| 1 |
| 1 |
| 0 |
| Laptops for instruments |
| 5 |
| 5 |
| 0 |
NAICS Code: 325413 - In-Vitro Diagnostic Substance Manufacturing. The small business size standard, for NAICS Code 339112, is 1,250 employees.
There are no set aside restrictions for this requirement. This notice of intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed 1 (8.5 x 11 inch) page using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract.
Capability statements are due by 11:00 AM Eastern Time, 05 August 2022. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word, Microsoft Excel or Adobe PDF attachment to Sheri Vendemia at the following e-mail address: Sheri.r.vendemia.civ@mail.mil.